Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
clinical trials
fda
indiana blog main
indiana top stories
life sciences
national blog main
raleigh-durham blog main
8
×
raleigh-durham top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
national
eli lilly
amgen
cancer
drugs
migraine research foundation
teva pharmaceutical
calcitonin gene-related peptide
chronic migraine
deals
eptinezumab
erenumab
What
drug
8
×
fda
8
×
approval
new
won
approved
migraine
bio
cancer
class
companies
decades
developed
drugs
friday
medicine
news
oks
oral
patients
roundup
second
therapy
time
acute
addresses
agency
aimmune
allergy
amgen
aren’t
arguments
awarded
big
candidates
causes
commercialized
competitors
condition
deeper
Language
unset
Current search:
fda
×
drug
×
" raleigh-durham blog main "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines